Drugs take the spotlight in steering clinical, economic direction for ESRD
Neumann, M.E.
Nephrology News and Issues 18(7): 50-51
2004
ISSN/ISBN: 0896-1263 PMID: 15232997 Document Number: 582803
Document emailed within 1 workday
Related Documents
Aagaard, G.N. 1973: Drug spotlight on psychotherapeutic drugs Annals of Internal Medicine 79(1): 130Garofolo, W.; Lam, H.; Garofolo, F. 2009: Society spotlight: Spotlight on the calibration and validation group Bioanalysis 1(3): 517-519
Pugh, J. 1995: Minorities and ESRD. Part I. Tracking the causes of ESRD in the Hispanic population Nephrology News and Issues 9(9): 34
Gao, X.; Jiang, Z.; Fu, Z. 1995: Lymphatic metastasis in central direction and bowel axial direction in colonic cancers Zhonghua Zhong Liu Za Zhi 17(5): 387-390
Tan, K.L. 1975: Comparison of the effectiveness of single-direction and double-direction phototherapy for neonatal jaundice Pediatrics 56(4): 550-553
Rocco, M.V.; Frankenfield, D.L.; Frederick, P.R.; Pugh, J.; McClellan, W.M.; Owen, W.F. 2000: Intermediate outcomes by race and ethnicity in peritoneal dialysis patients: results from the 1997 ESRD Core Indicators Project. National ESRD Core Indicators Workgroup Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis 20(3): 328-335
Wish, J.B. 2008: New ESRD clinical performance measures and data collection system: progress and pitfalls Nephrology News and Issues 22(8): 12-13
Kiro, A.; Robinson, G.; Laks, J.; Mor, Z.; Varsano, N.; Mendelson, E.; Amitai, Z.S. 2008: Morbidity and the economic burden of influenza in children in Israel--a clinical, virologic and economic review Harefuah 147(12): 960
2002: Inching up. Annual sampling of clinical indicators for ESRD patients shows continuing improvement Nephrology News and Issues 16(4): 13-18
Harumi, K.; Okamoto, Y. 1995: Clinical utility of body surface potential mapping and its new direction of research Nihon Rinsho. Japanese Journal of Clinical Medicine 53(1): 5-13
Sonne, J.; Faber, O. 2004: Economic prescription of drugs Ugeskrift for Laeger 166(18): 1695
Clavero González, G. 1973: Economic aspects of drugs Revista de Sanidad E Higiene Publica 47(4): 291-296
Grem, J.L.; Hoth, D.F.; Hamilton, J.M.; King, S.A.; Leyland-Jones, B. 1987: Overview of current status and future direction of clinical trials with 5-fluorouracil in combination with folinic acid Cancer Treatment Reports 71(12): 1249-1264
Evans, W.K.; Coyle, D.; Gafni, A.; Walker, H. 2003: Which cancer clinical trials should be considered for economic evaluation? Selection criteria from the National Cancer Institute of Canada's Working Group on Economic Analysis Chronic diseases in Canada 24(4): 102-107
Porter, R.J. 1998: Economic factors in the development of new antiepileptic drugs Advances in Neurology 76: 239-244
Andreasen, B. 1975: The new law for drugs in the European Economic Community and Denmark Ugeskrift for Laeger 137(43): 2536-2537
Prendergast, M.M. 2000: Sources of bias in the economic analysis of new drugs JAMA 283(11): 1424
Le Pen, C. 2000: Sources of bias in the economic analysis of new drugs JAMA 283(11): 1423-1424
Laux, G. 2003: Pharmaco-economic aspects of antidepressants and antipsychotic drugs Psychiatrische Praxis 30(Suppl 2): S90-S93
Dławichowska, E.; Owczarek, K.; Fiszer, U. 2001: Social and economic aspects of administration of new antiepileptic drugs Neurologia i Neurochirurgia Polska 35(2): 245-252